The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

9 Foods to Restrain the Hepatitis C Virus

Back to News Homepage

Next

Phase III Trial Results for Ally-1 Reveal High HCV Cure Rates

Merck’s Hepatitis C Drug Works

Print this page

Learn more about grazoprevir/elbasvir, Merck’s Hepatitis C drug that has been fast-tracked for FDA approval.

FDA Grants Breakthrough Designations to Merck’s Hepatitis C Candidate

The FDA has granted 2 breakthrough therapy designations to Merck’s chronic hepatitis C virus (HCV) candidate, grazoprevir/elbasvir.

The once-daily, single-tablet regimen originally received breakthrough therapy status for the treatment of chronic HCV genotype 1 (GT1) infection in October 2013. However, the FDA rescinded it in January 2015.

Continue reading this entire article:
http://www.pharmacytimes.com/product-news/FDA-Grants-Breakthrough-Designations-to-Mercks-Hepatitis-C-Candidate

21 Comments
Share
Share

Previous

9 Foods to Restrain the Hepatitis C Virus

Back to News Homepage

Next

Phase III Trial Results for Ally-1 Reveal High HCV Cure Rates

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.